[HTML][HTML] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations

AK Daly, AE Rettie, DM Fowler, JO Miners - Journal of personalized …, 2017 - mdpi.com
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …

[HTML][HTML] Genome interpretation using in silico predictors of variant impact

P Katsonis, K Wilhelm, A Williams, O Lichtarge - Human genetics, 2022 - Springer
Estimating the effects of variants found in disease driver genes opens the door to
personalized therapeutic opportunities. Clinical associations and laboratory experiments …

[HTML][HTML] Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors

D Lagorce, D Douguet, MA Miteva, BO Villoutreix - Scientific reports, 2017 - nature.com
The modulation of PPIs by low molecular weight chemical compounds, particularly by orally
bioavailable molecules, would be very valuable in numerous disease indications. However …

[HTML][HTML] Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of …

VM Pratt, LH Cavallari, AL Del Tredici, H Hachad… - The Journal of Molecular …, 2019 - Elsevier
The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working
Group of the Association for Molecular Pathology Clinical Practice Committee are to define …

Recent Advances of DprE1 Inhibitors against Mycobacterium tuberculosis: Computational Analysis of Physicochemical and ADMET Properties

PSM Amado, C Woodley, MLS Cristiano, PM O'Neill - ACS omega, 2022 - ACS Publications
Decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) is a critical flavoenzyme in
Mycobacterium tuberculosis, catalyzing a vital step in the production of lipoarabinomannan …

[HTML][HTML] Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism

A Isvoran, Y Peng, S Ceauranu, L Schmidt, AB Nicot… - Drug Discovery …, 2022 - Elsevier
Sulfotransferases (SULTs) are Phase II drug-metabolizing enzymes (DMEs) catalyzing the
sulfation of a variety of endogenous compounds, natural products, and drugs. Various drugs …

Analysis of protein missense alterations by combining sequence‐and structure‐based methods

A Gyulkhandanyan, AR Rezaie… - … Genetics & Genomic …, 2020 - Wiley Online Library
Background Different types of in silico approaches can be used to predict the phenotypic
consequence of missense variants. Such algorithms are often categorized as sequence …

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta‐analysis

Y Zhang, K Hou, F Liu, X Luo, S He, L Hu, C Yang… - Mycoses, 2021 - Wiley Online Library
Background Voriconazole primary metabolism is catalysed by CYP2C19. A large variability
of trough concentrations in patients with invasive fungal infection treated with voriconazole …

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy

JR Amsden, PO Gubbins - Expert opinion on drug metabolism & …, 2017 - Taylor & Francis
Introduction: Triazole antifungal agents are prescribed to treat invasive fungal infections in
neutropenic and non-neutropenic patients. These antifungal agents are substrates and …

[HTML][HTML] Exploring the molecular structure, vibrational spectroscopic, quantum chemical calculation and molecular docking studies of curcumin: A potential PI3K/AKT …

M Govindammal, M Prasath, S Kamaraj, S Muthu… - Heliyon, 2021 - cell.com
The IUPAC name of curcumin is (1E, 6E)-1, 7-Bis (4-hydroxy-3methoxyphenyl) hepta-1, 6-e-
3, 5-dione (7B3M5D) and is characterized by spectroscopic profiling with FT-IR and FT …